HC Wainwright Analysts Give Protalix Biotherapeutics (PLX) a $4.00 Price Target

Protalix Biotherapeutics (NYSEAMERICAN:PLX) has been given a $4.00 price target by HC Wainwright in a report issued on Tuesday. The firm presently has a “buy” rating on the stock.

Separately, Zacks Investment Research lowered Protalix Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th.

NYSEAMERICAN PLX opened at $0.65 on Tuesday. Protalix Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $0.92.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its quarterly earnings results on Thursday, August 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $2.01 million during the quarter, compared to analysts’ expectations of $7.00 million.

A hedge fund recently bought a new stake in Protalix Biotherapeutics stock. SG Americas Securities LLC acquired a new position in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 225,000 shares of the company’s stock, valued at approximately $121,000. SG Americas Securities LLC owned about 0.15% of Protalix Biotherapeutics at the end of the most recent reporting period.

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Further Reading: How much money do you need to begin day trading?

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply